Regenxbio Inc risk profile
60 Stretched several inputs deteriorating together
Measured 21 October 2026 from RGNX's filed statements. Recomputed nightly.
60 (Stretched), driven by Cash conversion at 100, over 6 weighted categories on the MANUFACTURER profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 79 | Stretched | Volatile | One-year price volatility — 91.6% |
| Operating pressure | 0 | Contained | Easing | Costs outgrowing revenue — -100.5 percentage points |
| Cash conversion | 100 | Acute | Stable | Capital spending against operating cash — -0.02x |
| Leverage and coverage | 86 | Acute | Stable | Net debt to EBITDA |
| Competitive position | 54 | Elevated | Stable | Operating-margin gap against peers — -91.2 percentage points |
| Concentration | 80 | Acute | Easing | Customer concentration — 4,901 HHI |
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.